drugset
drugset / Trial / NCT00724334

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

NCT00724334 ↗

Phase 1/2 Completed 42 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.

Timeline

Start
2008-07
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Fedratinib Small molecule — Oral

Indications

myelofibrosis